NCT06196697View on ClinicalTrials.gov

AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 10, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

March 31, 2027

Conditions
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Interventions
BIOLOGICAL

Cadonilimab

Subjects will receive AK104 by intravenous administration

BIOLOGICAL

Ivonescimab

Subjects will receive AK112 by intravenous administration

DRUG

XELOX

Subjects will receive AK104 and AK112 in combination with XELOX(oxaliplatin and capecitabine)

DRUG

SOX

Subjects will receive AK104 and AK112 in combination withSOX(oxaliplatin and Tegafur)

Trial Locations (1)

Unknown

RECRUITING

Harbin Medical University Hospital, Harbin

All Listed Sponsors
lead

Harbin Medical University

OTHER